Beddow Capital Management Inc. Sells 6,625 Shares of CVS Health Co. (NYSE:CVS)

Beddow Capital Management Inc. lowered its holdings in CVS Health Co. (NYSE:CVS) by 12.2% during the third quarter, Holdings Channel reports. The fund owned 47,510 shares of the pharmacy operator’s stock after selling 6,625 shares during the quarter. CVS Health makes up 1.2% of Beddow Capital Management Inc.’s holdings, making the stock its 28th largest holding. Beddow Capital Management Inc.’s holdings in CVS Health were worth $2,987,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bahl & Gaynor Inc. increased its stake in shares of CVS Health by 11.9% in the 1st quarter. Bahl & Gaynor Inc. now owns 15,833 shares of the pharmacy operator’s stock valued at $1,263,000 after purchasing an additional 1,680 shares in the last quarter. O Shaughnessy Asset Management LLC increased its holdings in CVS Health by 34.9% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 86,556 shares of the pharmacy operator’s stock worth $6,904,000 after acquiring an additional 22,400 shares in the last quarter. Bessemer Group Inc. lifted its holdings in CVS Health by 55.5% during the first quarter. Bessemer Group Inc. now owns 73,343 shares of the pharmacy operator’s stock valued at $5,849,000 after purchasing an additional 26,173 shares in the last quarter. Lake Street Advisors Group LLC increased its stake in shares of CVS Health by 29.3% during the first quarter. Lake Street Advisors Group LLC now owns 12,917 shares of the pharmacy operator’s stock worth $1,030,000 after purchasing an additional 2,930 shares in the last quarter. Finally, Crewe Advisors LLC acquired a new position in shares of CVS Health during the 1st quarter worth about $40,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Up 5.4 %

CVS opened at $56.08 on Tuesday. The business’s 50 day moving average is $59.19 and its two-hundred day moving average is $58.60. The firm has a market cap of $70.57 billion, a price-to-earnings ratio of 14.23, a price-to-earnings-growth ratio of 0.92 and a beta of 0.55. CVS Health Co. has a 52 week low of $52.71 and a 52 week high of $83.25. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.08 by $0.01. The firm had revenue of $95.43 billion during the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. During the same period in the prior year, the business earned $2.21 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. On average, research analysts predict that CVS Health Co. will post 5.48 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were given a $0.665 dividend. The ex-dividend date was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a yield of 4.74%. CVS Health’s payout ratio is currently 67.51%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Evercore ISI boosted their price target on CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Cantor Fitzgerald reissued a “neutral” rating and set a $62.00 price objective on shares of CVS Health in a research note on Tuesday, October 1st. Mizuho reduced their price target on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a research report on Friday, August 9th. Finally, Truist Financial lifted their target price on CVS Health from $66.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, October 11th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $72.78.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.